GENinCode Plc (GENI) · 2026-08-28

CARDIO inCode-Score milestone clinical results

GENinCode Plc said its CARDIO inCode-Score pilot in 584 primary-care patients reduced mean cardiovascular risk from 7.30% to 6.04% after a mean 8.5 months.

GENinCode Plc (GENI) · 2026-06-08

Final Results

GENinCode reported 14% revenue growth to £3.1m for 2025, driven by US and EU volume. Adjusted EBITDA loss widened to £4.9m due to commercial expansion. Cash was £0.8m at year-end, subsequently replenished by a £4.7m post-period fundraise.